Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Vorsetuzumab (anti-CD70)
Price:
Purity: 95.0%
Stocking Period: 10 Day
Contact: Huang

1165740-62-4

1165740-62-4 structure

1165740-62-4 structure

Name: Vorsetuzumab
Chemical Name: Vorsetuzumab
CAS Number: 1165740-62-4
Molecular Formula:
Molecular Weight: 146.1 (kDa)
Catalog: Research Areas Cancer
Create Date: 2023-01-20 13:05:43
Modify Date: 2024-04-09 18:55:07
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma[1].

Name	Vorsetuzumab

Description	Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
Target	CD70[1]
In Vitro	Vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells in vitro[1]. Vorsetuzumab (10 μg/mL; 2 h) can be developed into bispecific anti-human CD70/KWAR23 antibody, results KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1)[1].
In Vivo	Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt’s lymphoma cell growth growth in SRG mice[1]. Animal Model: Burkitt’s lymphoma xenograft model in SRG mice[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; every other day; for 12 d Result: Effectively inhibited Burkitt’s lymphoma cell growth but was not outperform the combination of the KWAR23 antibody (10 mg/kg).
References	[1]. Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.

Molecular Weight	146.1 (kDa)